This application is a continuation of U.S. Pat. No. 10,405,992, issued on Sep. 10, 2019 and entitled “Spinal Fusion Implant,” the entire disclosure of which is hereby incorporated by reference.
The embodiments are generally directed to implants for supporting bone growth in a patient.
A variety of different implants are used in the body. Implants used in the body to stabilize an area and promote bone ingrowth provide both stability (i.e. minimal deformation under pressure over time) and space for bone ingrowth.
Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical treatment method used for the treatment of various morbidities such as degenerative disc disease, spondylolisthesis (slippage of a vertebra), spinal stenosis, scoliosis, fracture, infection or tumor. The aim of the spinal fusion procedure is to reduce instability and thus pain.
In preparation for the spinal fusion, most of the intervertebral disc is removed. An implant, the spinal fusion cage, may be placed between the vertebra to maintain spine alignment and disc height. The fusion (i.e. bone bridge) occurs between the endplates of the vertebrae.
In one aspect, an implant includes a housing, where the housing has a first axis, a blade, the blade having a retracted position in the housing and an extended position where the blade extends outwardly from the housing, and a blade actuating component, where the blade actuating component includes a driven shaft portion and a blade engaging portion. The blade actuating component can move the blade between the retracted position and the extended position. In addition, the housing includes a first end, where the first end includes a guide opening, and the guide opening has a hollow grooved portion and a chamber portion. The hollow grooved portion is connected to the chamber portion, and the chamber portion receives a portion of the driven shaft portion of the blade actuating component.
In another aspect, an implant includes a body having a first axis, and a blade having a retracted position in the body and an extended position where the blade extends outwardly from the body. The blade has a distal face and a proximal face. In addition, the blade has a bridge portion disposed adjacent to the distal face, where the bridge portion is configured to provide structural reinforcement to the blade. The implant further includes a blade actuating component that can translate through the body in directions parallel to the first axis, and the blade actuating component can move the blade between the retracted position and the extended position.
In another aspect, an implant includes a housing, a first blade, and a blade actuating component. The first blade has a retracted position in the housing and an extended position where the first blade extends outwardly from the housing. In addition, the blade actuating component is configured to translate through the housing in directions parallel to a first axis, where the first axis extends from an anterior side of the implant to a posterior side of the implant. The blade actuating component comprises a driven shaft portion and a blade engaging portion, the driven shaft portion being disposed at least partially outside of the housing when the first blade is the retracted position, and the driven shaft portion being disposed entirely within the housing when the first blade is in the extended position.
Other systems, methods, features and advantages of the embodiments will be, or will become, apparent to one of ordinary skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description and this summary, be within the scope of the embodiments, and be protected by the following claims.
The embodiments can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, with emphasis instead being placed upon illustrating the principles of the embodiments. Moreover, in the figures, like reference numerals designate corresponding parts throughout the different views.
The embodiments described herein are directed to an implant for use in a spine. The embodiments include implants with a body and one or more blades. In addition to the various provisions discussed below, any embodiments may make use of any of the body/support structures, blades, actuating components or other structures disclosed in Duffield et al., U.S. Pat. No. 9,707,100, issued on Jul. 18, 2017 and titled “Interbody Fusion Device and System for Implantation,” Sack, U.S. Pat. No. 10,307,265, issued on Jun. 4, 2019 and titled “Implant With Deployable Blades,” and Duffield et al., U.S. Patent Publication Number 2017/0100260, published on Apr. 13, 2017 and titled “Insertion Tool For Implant And Methods of Use,” each of which are hereby incorporated by reference in their entirety.
Introduction to the Implant
In some embodiments, implant 100 may be inserted using an anterior lumbar interbody fusion (ALIF) surgical procedure, where the disc space is fused by approaching the spine through the abdomen. In the ALIF approach, a three-inch to five-inch incision is typically made near the abdomen and the abdominal muscles are retracted to the side. In some cases, implant 100 can be inserted through a small incision in the front or anterior side of the body. In some cases, an anterior approach may afford improved exposure to the disc space to a surgeon. The anterior approach can allow a larger device to be used for the fusion, increasing the surface area for a fusion to occur and allowing for more postoperative stability. An anterior approach often makes it possible to reduce some of the deformity caused by various conditions, such as isthmic spondylolisthesis. Insertion and placement of the disc along the front of a human body can also re-establish the patient's normal sagittal alignment in some cases, giving individuals a more normal inward curve to their low back.
For purposes of clarity, reference is made to various directional adjectives throughout the detailed description and in the claims. As used herein, the term “anterior” refers to a side or portion of an implant that is intended to be oriented towards the front of the human body when the implant has been placed in the body. Likewise, the term “posterior” refers to a side or portion of an implant that is intended to be oriented towards the back of the human body following implantation. In addition, the term “superior” refers to a side or portion of an implant that is intended to be oriented towards a top (e.g., the head) of the body while “inferior” refers to a side or portion of an implant that is intended to be oriented towards a bottom of the body. Reference is also made herein to “lateral” sides or portions of an implant, which are sides or portions facing along a lateral direction of the body.
Reference is also made to directions or axes that are relative to the implant itself, rather than to its intended orientation with regards to the body. For example, the term “distal” refers to a part that is located further from a center of an implant, while the term “proximal” refers to a part that is located closer to the center of the implant. As used herein, the “center of the implant” could be the center of mass and/or a central plane and/or another centrally located reference surface.
An implant may also be associated with various axes. Referring to
An implant may also be associated with various reference planes or surfaces. As used herein, the term “median plane” refers to a vertical plane which passes from the anterior side to the posterior side of the implant, dividing the implant into right and left halves, or lateral halves. As used herein, the term “transverse plane” refers to a horizontal plane located in the center of the implant that divides the implant into superior and inferior halves. As used herein, the term “coronal plane” refers to a vertical plane located in the center of the implant that divides the implant into anterior and posterior halves. In some embodiments, the implant is symmetric or substantially symmetric about two planes, such as the median and the transverse plane.
Embodiments of an implant may include provisions for anchoring the implant into adjacent vertebral bodies. In some embodiments, an implant may include one or more anchoring members. In the embodiment of
An implant with blades can include provisions for moving the blades with respect to a housing of the implant. In some embodiments, an implant includes a blade actuating component that engages with one or more blades to extend and/or retract the blades from the surfaces of the implant. In the embodiment shown in
An implant can include provisions for locking the position of one or more elements of the implant. In embodiments where the position of a blade actuating component can be changed, an implant can include provisions for locking the actuating component in a given position, thereby also locking one or more blades in a given position, such as through the use of a threaded fastener or other type of securing mechanism. In the embodiment shown in
Embodiments can also include one or more fasteners that help attach a body to a cover. In some embodiments, pins, screws, nails, bolts, clips, or any other kinds of fasteners could be used. In the embodiment shown in
Body Component
Referring now to
In some embodiments, the lateral sides of a body may both have a lattice-like geometry. Various openings or apertures, as will be discussed below, can help reduce the overall weight of the implant, and/or decrease manufacturing costs associated with material usage. Furthermore, in some cases, openings can increase the surface area available throughout body 200, and facilitate the application of bone growth promoting materials to the implant, and/or facilitate the coupling of the implant with the insertion tool, as will be discussed further below. In some other embodiments, the lateral sides could be configured as solid walls with one or more openings. Furthermore, by providing openings in the housing of the implant, there can be improved visual clarity regarding the degree or extent of blade deployment.
In the exemplary embodiment shown in
In addition, as shown in
Referring back to
As shown in
In some embodiments, as will be discussed further below and is shown generally in
Body 200 can also include additional reinforcement structures. For example, as shown in
Furthermore, in some embodiments, first inner sidewall 634 and second inner sidewall 636 can help define or bound a central hollow region 638 in body 200. Central hollow region 638 can extend through the thickness of body 200. Central hollow region 638 can be configured to receive the blades and the blade actuating component, as will be discussed further below. In
In different embodiments, posterior opening 642 can be disposed between a first end portion 696 and a second end portion 698 that are associated with posterior side 112 of body 200. Furthermore, in some embodiments, each end portion can include a recessed region. In
First end portion 696 and a second end portion 698 can be substantially similar in some embodiments. In one embodiment, first end portion 696 and a second end portion 698 are mirror-images of one another relative to a central posterior-anterior axis or midline. In some embodiments, first posterior recess 692 and second posterior recess 694 are sized and dimensioned to snugly receive a rearward cover or cap that extends between or bridges together first end portion 696 and second end portion 698 of body 200, providing a substantially continuous outer periphery of the implant. In addition, in some embodiments, either or both of first end portion 696 and second end portion 698 can include pin holes (shown in
The configuration of body 200 shown for the embodiment of
Embodiments can also include one or more blade retaining portions. A blade retaining portion may receive any part of a blade, including one or more edges and/or faces of the blade. In one embodiment, a body includes blade retaining portions to receive the anterior and posterior edges of each blade. As seen in
In some embodiments, one or more channels can be oriented in a direction that is substantially diagonal relative to the horizontal plane. In one embodiment, a channel can be oriented approximately 45 degrees relative to the horizontal plane. In other embodiments, a channel can be oriented vertically (approximately 90 degrees relative to the horizontal plane) or can be oriented between 30 degrees and 90 degrees relative to the horizontal plane. The orientation of a channel can be configured to correspond to the orientation of the anterior edges and/or posterior edges of a blade in some embodiments.
Body 200 also includes third blade retaining portion 604 and fourth retaining portion 606 for receiving the anterior and posterior edges of the second blade. This configuration may help maximize available bone graft volume within the implant since the lateral edges of the blades serve as tracks for translation. Specifically, this limits the need for additional track members on the blade that would take up additional volume in the implant. Furthermore, the arrangement of the retaining channels and the associated blade edges results in most of the volume of the retaining channels being filled by the blade edges in the retracted position, which helps prevent any graft material or BGPM (details on the effect and use of bone growth promoting material will be discussed further below) from entering the retaining channels and inhibiting normal blade travel.
Blades and Blade Actuating Component
In some embodiments, driven end 262 can include one or more engaging features. For example, driven shaft portion 320 can include a threaded opening 267 that is accessible from driven end 262, as best seen in
In addition, driven shaft portion 320 can be substantially elongated and/or narrow relative to blade engaging portion 322. For example, in
Furthermore, as will be discussed further below with respect to
A blade actuating component can include provisions for coupling with one or more blades. In some embodiments, a blade actuating component can include one or more channels. In the exemplary embodiment of
In addition, referring to
In different embodiments, the geometry of a blade could vary. In some embodiments, a blade could have a substantially planar geometry such that the distal face and the proximal face of the blade are each parallel with a common plane, as best shown in
Furthermore, in some embodiments, blade 241 can include provisions for increasing the support or structural strength of blade 241. In one embodiment, blade 241 includes a bridge portion 1350 that is disposed or formed on distal face 408. Referring to
In some embodiments, bridge portion 1350 includes a relatively wide U-shaped or curved V-shaped outer sidewall 1370. In
Bridge portion 1350 can also be substantially symmetrical in some embodiments. For example, in
In the exemplary embodiment, the outer edge 400 is a penetrating edge configured to be implanted within an adjacent vertebral body. To maximize penetration, outer edge 400 may be sharpened so that blade 241 has an angled surface 409 adjacent outer edge 400. Moreover, in some embodiments, anterior edge 404 and posterior edge 406 are also sharpened in a similar manner to outer edge 400 and may act as extensions of outer edge 400 to help improve strength and penetration. It can be understood that, in some embodiments, bridge portion 1350 can also serve to help prevent the blades from extending further outward into a vertebrae downward once they reach the desired deployment extension.
A blade can further include provisions for coupling with a blade actuating component. In some embodiments, a blade can include a protruding portion. In some embodiments, the protruding portion can extend away from a face of the blade and may fit within a channel in a blade actuating component. Referring to
A protruding portion may be oriented at an angle on a blade so as to fit with an angled channel in a blade actuating component. In the embodiment of
Although the above discussion is directed to first blade 241, it may be appreciated that similar principles apply for second blade 242. In particular, in some embodiments, second blade 242 may have a substantially identical geometry to first blade 241. Furthermore, while reference is made to a superior side and inferior side with respect to the first blade, it will be understood that, in some embodiments, the orientation of the second blade can differ such that the inner edge is associated with the inferior side and the outer edge is associated with the superior side.
As noted above, each blade may be associated with the blade engaging portion of the blade actuating component. In
Each channel that is formed in blade engaging portion 322 is seen to extend at an angle between superior surface 330 and inferior surface 332 of blade engaging portion 322. For example, as best seen in
In different embodiments, the angle of each channel could be selected to provide proper blade extension for varying implant sizes. As used herein, the angle of a channel is defined to be the angle formed between the channel and a transverse plane of the blade actuating component. In the embodiment of
In different embodiments, the angle of each channel could vary. In some embodiments, a channel could be oriented at any angle between 15 and 75 degrees. In other embodiments, a channel could be oriented at any angle between 35 and 65 degrees. Moreover, in some embodiments, the angle of a channel may determine the angle of a protruding portion in a corresponding blade. For example, protruding angle 459 formed between protruding portion 450 and inner edge 402 of blade 241 (see
Furthermore, as seen in
Each channel may be associated with a first channel direction and an opposing second channel direction. For example, as best seen in
With first protruding portion 450 of first blade 241 disposed in first channel 350, first protruding portion 450 can slide in first channel direction 460 or second channel direction 462. As first protruding portion 450 slides in first channel direction 460, first blade 241 moves vertically with respect to blade actuating component 260 such that first blade 241 extends outwardly on a superior side of the implant to a deployed position (see
As shown in the cross section of
In some embodiments, each protruding portion forms a sliding dovetail connection or joint with a corresponding channel. Using dovetail tracks on the blade actuating component and corresponding dovetail features on the posterior and anterior blades allows axial movement along the angle of inclination while preventing disengagement under loads encountered during blade impaction and retraction. For example, in
It may be appreciated that in other embodiments, the geometry of the interconnecting parts between a blade and a blade actuating component could be reversed. For example, in another embodiment, a blade could comprise one or more channels and a blade actuating component could include corresponding protrusions to fit in the channels. In such embodiments, both the protruding portion of the blade actuating component and the channels in the blades could have corresponding dovetail geometries.
Body and Cover
As discussed above with respect to
Insertion Position and Deployed Position of Implant
As noted above, the embodiments described herein provide an implant that can move from a first position (the “insertion position”), which allows the implant to maintain a low profile, to a second position (the “impaction position” or the “deployed position”), that deploys the blades and inserts them into the proximal superior and inferior vertebral bodies. While the implant is in the first (insertion) position, the blades of the device may be retracted within the body of the implant (i.e., the blades may themselves be in a “retracted position”). In the second (deployed) position of the implant, the blades extend superiorly (or cranially) or inferiorly (or caudally) beyond the implant and into the vertebral bodies to prevent the implant from moving out of position over time. Thus, the blades themselves may be said to be in an “extended position” or “deployed position”. When the blades are deployed, the implant resists left to right rotation and resists flexion and/or extension. It may be appreciated that although the blades may approximately move in vertical directions (i.e., the superior and inferior directions), the actual direction of travel may vary from one embodiment to another. For example, in some embodiments the blades may be slightly angled within the implant and may deploy at slight angles relative to a vertical direction (or to the inferior/superior directions).
In some embodiments, one or more blades could be deployed at a slight angle, relative to the normal directions on the superior and inferior surfaces of the implant. In some embodiments, one or more blades could be oriented at an angle between 0 and 30 degrees. In other embodiments, one or more blades could be oriented at an angle that is greater than 30 degrees. In the exemplary embodiment shown in
The extension of each blade could vary in different embodiments. In some embodiments, a blade could extend outwardly by a length between 0 and 100% of the depth of an implant. In still other embodiments, combined blade height could extend outwardly by a length between 100 and 130% of the depth of an implant. In the exemplary embodiment shown in
Furthermore, as disclosed in the “Implant With Deployable Blades” application, in some embodiments, implant 100 can use a three-point attachment configuration for each of first blade 241 and second blade 242. Specifically, each blade is received along its lateral edges by two blade retaining portions, and also coupled to blade actuating component 260 using the dovetail connection described above. In other words, anterior edge 404 of first blade 241 is received within the first blade retaining channel of first blade retaining portion 600. Posterior edge 406 of first blade 241 is received within a second retaining channel of second blade retaining portion 602. Moreover, distal face 408 of first blade 241 remains unattached to any other elements of implant 100. Not only does first blade 241 remain unattached along distal face 408, but the entirety of distal face 408 between anterior edge 404 and posterior edge 406 is spaced apart from (i.e., not in contact with) all other elements of implant 100. Further, second blade 242 is likewise attached at its lateral edges to corresponding blade retaining portions and also coupled to blade actuating component 260 using a sliding dovetail connection. Thus, first blade 241 and second blade 242 are held in implant 100 using a three-point attachment configuration that may limit unwanted friction on first blade 241 and second blade 242 during impaction. It may be appreciated that the fit between each blade and each blade retaining channel may provide sufficient clearance to allow for translation of the blades along the retaining channels. In other words, the fit may not be so tight as to impede movement of the lateral edges within the retaining channels.
In different embodiments, the cross-sectional geometry of channels in one or more blade retaining portions could vary. In some embodiments, the cross-sectional geometry could be rounded. In the embodiments disclosed herein, first blade retaining portion 600 (see
Using an interlocking joint, such as a dovetail sliding joint, to connect the blades and a blade actuating component helps prevent the blades from decoupling from the blade actuating component during impact. Additionally, with an interlocking joint the blade actuating component can be used to retract the blades.
In
Furthermore, the interlocking connection between first protruding portion 450 and first channel 350 (as well as between second protruding portion 455 and second channel 352) means that both blades remain coupled to the motion of blade actuating component 260 at all times. It should be noted that since both blades are restricted from moving in a longitudinal direction, the resulting motion of each blade is purely vertical. Moreover, using the dovetail shaped protruding portions for each blade means the protruding portions are both lifting at the center line to limit any cocking force or rotational moments that could result in increased (friction) resistance to motion or binding of these moving parts.
Using this configuration, the forces deploying the blades are balanced through the blade actuating component 260 in order to minimize friction and binding between driven shaft portion 320 and the guide opening in body 200 (see
In
It may be appreciated that in some embodiments a blade actuating component (e.g., blade actuating component 260) may function to support adjacent vertebral bodies. This is can be accomplished by using a blade actuating component with a height similar to the height of the outer support structure so that the superior and inferior surfaces of the blade actuating component may come into contact with the vertebral bodies following implantation. Since the blade actuating component functions as a load bearing structure within the implant, this may free up additional space in the implant otherwise occupied by additional support structures, thereby increasing the internal volume available for bone graft or BGPMs.
Referring to
As noted above, body 200 may include guide opening 222 that receives a portion of blade actuating component 260. When the implant is in the deployed position, the driven shaft portion can be disposed securely in the chamber portion. In some embodiments, the chamber portion of guide opening 222 may have a shape that matches the cross-sectional shape of a driven shaft portion of a blade actuating component. In some embodiments, both the chamber portion and the driven shaft portion of the blade actuating component have rectangular cross-sectional shapes (see
Locking Screw
Implant 100 can include provisions for securing the implant 100 in the deployed position. Referring to the exploded isometric view of
Alternate Blade Actuating Component
In different embodiments, an implant can utilize different types of components to provide the features and functions described herein. In some embodiments, the features of blade actuating component can be adjusted in order to facilitate the use of implant with a variety of surgical requirements. For example, in some embodiments, an alternate embodiment of a second blade actuating component (“second actuating component”) 3300 can be placed within the housing of the body, as shown in
In addition, to allow an implant to withstand varying forces and work with different blade types, the height and/or other dimensions of the blade engaging portion can be increased or decreased. For example, in
In order to provide greater detail with respect to the initial insertion position and the deployed position,
However, when an impacting force is applied to driven end 262, the substantial entirety of second actuating component 3300 can be disposed within the internal space of the body. Furthermore, actuating posterior end 1200 can move translationally from the main opening of the central hollow region in body 200 toward the posterior opening. It can be seen that a portion of posterior opening 642 is filled with or bridged by a central portion of cover 220. As actuating posterior end 1200 approaches the posterior opening, receiving portion 1210 comprising the two-pronged mouth shown in
Furthermore, as noted above, in
Insertion Process
As noted above, embodiments of implant 100 can make use of features or structures disclosed in the “Insertion Tool For Implant And Methods of Use” application. In some embodiments, implant 100 can be configured for use with a single tool that can significantly facilitate the implantation process. For example, whether a surgeon approaches the disc space from an anterior approach can be dependent on how comfortable the surgeon is with the anterior approach and operating around the aorta and vena cava. By approaching a patient from the anterior side, there can be a risk of vessel injury, as the aorta and vena cava lie in front of the spine. However, the benefits of added stability and fusion area very often outweigh the risks of the extra surgery, and the process of deployment provided herein can help lower such risks.
In some embodiments, body 200 may include attachment points for an insertion instrument. In
Body 200 may include provisions for interacting with insertion tool 3600. For example, as seen in
Implant Dimensions
In different embodiments, the size of an implant could vary. In some embodiments, an implant could have any length. Embodiments could have lengths ranging from 40 mm to 60 mm. In some cases, a manufacturer could provide multiple implant options with lengths varying between 40 mm and 60 mm in 5 mm increments. In some embodiments, an implant could have any height. Embodiments could have a height ranging from 4 mm to 16 mm. In some cases, a manufacturer could provide implants with heights varying from 4 mm to 16 mm in 2 mm increments. Embodiments could have widths (i.e., size along the posterior-anterior axis) of 18 mm, 22 mm, 26 mm as well as other sizes.
Embodiments can also be constructed with various lordosis angles, that is, angles of incline between the posterior and anterior sides. Embodiments could be configured with lordosis angles of 8, 15 and 20 degrees, for example. In other embodiments, other lordosis angles could be used for an implant. Furthermore, in some embodiments, the blades can be angled to accommodate additional implants or other implanted device in the spine that are located at adjacent levels, fostering stabilization in the patient's system.
Alignment Features
Embodiments may optionally include one or more alignment features. Exemplary alignment features include, but are not limited to, windows for fluoroscopy positioning, windows for blade deployment validation, windows for aligning a blade actuating component with one or more blades, as well as various other kinds of alignment features. Referring to
In some embodiments, the dovetail connections can help to more precisely control the blade position in both directions. Some embodiments of the implant may also include one or more stroke limiting stops. For example, there may be two stroke limiting stops formed on blade actuating component 260. These stops may help prevent over travel of blade actuating component 260. Specifically, a stroke limiting stop may contact the internal surfaces of body 200. In other words, the blade actuating component has a limited stroke dictated by the length of its distal portion and the inside depth of the implant, measured from the inside of the implant proximal wall and the inside surface of the cover that is pinned in place.
Materials
The various components of an implant may be fabricated from biocompatible materials suitable for implantation in a human body, including but not limited to, metals (e.g. titanium, titanium alloy, stainless steel, cobalt-chrome, or other metals), synthetic polymers (e.g. PEEK or PEKK), ceramics, and/or their combinations, depending on the particular application and/or preference of a medical practitioner.
Generally, the implant can be formed from any suitable biocompatible, non-degradable material with sufficient strength. Typical materials include, but are not limited to, titanium, biocompatible titanium alloys (e.g. Titanium Aluminides (including gamma Titanium Aluminides), Ti6—Al4—V ELI (ASTM F 136 and ASTM F 3001), or Ti6—Al4—V (ASTM F 1108, ASTM F 1472, and ASTM F 2989) and inert, biocompatible polymers, such as polyether ether ketone (PEEK) (e.g. PEEK-OPTIMA®, Invibio Inc, Zeniva®, Solvay Inc., or others). Optionally, the implant contains a radiopaque marker to facilitate visualization during imaging when constructed of radiolucent biomaterials.
In different embodiments, processes for making an implant can vary. In some embodiments, the entire implant may be manufactured and assembled via traditional and CNC machining, injection-molding, cast or injection molding, insert-molding, co-extrusion, pultrusion, transfer molding, overmolding, compression molding, 3-Dimensional (3-D) printing, dip-coating, spray-coating, powder-coating, porous-coating, milling from a solid stock material and their combinations.
In one embodiment, body 200 may be produced by Additive Manufacturing. Specifically, Direct Metal Laser Sintering (DMLS) using powder Ti-6Al-4V ELI, and then traditional or CNC machined in specific locations to precise dimensions. Moreover, in one embodiment, as shown in
Implantation
Some embodiments may use a bone growth promoting material, including bone graft or bone graft substitute material. As used herein, a “bone growth promoting material” (BGPM) is any material that helps bone growth. Bone growth promoting materials may include provisions that are freeze dried onto a surface or adhered to the metal through the use of linker molecules or a binder. Examples of bone growth promoting materials are any materials including bone morphogenetic proteins (BMPs), such as BMP-1, BMP-2, BMP-4, BMP-6, and BMP-7. These are hormones that convert stem cells into bone forming cells. Further examples include recombinant human BMPs (rhBMPs), such as rhBMP-2, rhBMP-4, and rhBMP-7. Still further examples include platelet derived growth factor (PDGF), fibroblast growth factor (FGF), collagen, BMP mimetic peptides, as well as RGD peptides. Generally, combinations of these chemicals may also be used. These chemicals can be applied using a sponge, matrix or gel.
Some bone growth promoting materials may also be applied to an implantable prosthesis through the use of a plasma spray or electrochemical techniques. Examples of these materials include, but are not limited to, hydroxyapatite, beta tri-calcium phosphate, calcium sulfate, calcium carbonate, as well as other chemicals.
A bone growth promoting material can include, or may be used in combination with a bone graft or a bone graft substitute. A variety of materials may serve as bone grafts or bone graft substitutes, including autografts (harvested from the iliac crest of the patient's body), allografts, demineralized bone matrix, and various synthetic materials.
Some embodiments may use autograft. Autograft provides the spinal fusion with calcium collagen scaffolding for the new bone to grow on (osteoconduction). Additionally, autograft contains bone-growing cells, mesenchymal stem cells and osteoblast that regenerate bone. Lastly, autograft contains bone-growing proteins, including bone morphogenic proteins (BMPs), to foster new bone growth in the patient.
Bone graft substitutes may comprise synthetic materials including calcium phosphates or hydroxyapatites, stem cell containing products which combine stem cells with one of the other classes of bone graft substitutes, and growth factor containing matrices such as INFUSE® (rhBMP-2-containing bone graft) from Medtronic, Inc.
It should be understood that the provisions listed here are not meant to be an exhaustive list of possible bone growth promoting materials, bone grafts or bone graft substitutes.
In some embodiments, BGPM may be applied to one or more outer surfaces of an implant. In other embodiments, BGPM may be applied to internal volumes within an implant. In still other embodiments, BGPM may be applied to both external surfaces and internally within an implant.
While various embodiments have been described, the description is intended to be exemplary, rather than limiting, and it will be apparent to those of ordinary skill in the art that many more embodiments and implementations are possible that are within the scope of the embodiments. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any embodiment may be used in combination with, or substituted for, any other feature or element in any other embodiment unless specifically restricted. Therefore, it will be understood that any of the features shown and/or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the embodiments are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.
Number | Name | Date | Kind |
---|---|---|---|
4554914 | Kapp et al. | Nov 1985 | A |
4599086 | Doty | Jul 1986 | A |
4636217 | Ogilvie et al. | Jan 1987 | A |
5443467 | Biedermann | Aug 1995 | A |
5522899 | Michelson | Jun 1996 | A |
5609635 | Michelson | Mar 1997 | A |
5653708 | Howland | Aug 1997 | A |
5667508 | Errico | Sep 1997 | A |
5683394 | Rinner | Nov 1997 | A |
5702391 | Lin | Dec 1997 | A |
5776199 | Michelson | Jul 1998 | A |
5800500 | Sertich | Sep 1998 | A |
5800547 | Schaefer et al. | Sep 1998 | A |
5800550 | Sertich | Sep 1998 | A |
5989254 | Katz | Nov 1999 | A |
6102949 | Biedermann et al. | Aug 2000 | A |
6102950 | Vaccaro | Aug 2000 | A |
6113601 | Tatar | Sep 2000 | A |
6113638 | Williams | Sep 2000 | A |
6179873 | Zientek | Jan 2001 | B1 |
6251140 | Marino | Jun 2001 | B1 |
6302914 | Michelson | Oct 2001 | B1 |
6371987 | Weiland et al. | Apr 2002 | B1 |
6447544 | Michelson | Sep 2002 | B1 |
6447546 | Bramlet | Sep 2002 | B1 |
6447547 | Michelson | Sep 2002 | B1 |
6454805 | Baccelli et al. | Sep 2002 | B1 |
6478823 | Michelson | Nov 2002 | B1 |
6520993 | James et al. | Feb 2003 | B2 |
6527803 | Crozet | Mar 2003 | B1 |
6565565 | Yuan | May 2003 | B1 |
6645207 | Dixon | Nov 2003 | B2 |
6652526 | Arafiles | Nov 2003 | B1 |
6656181 | Dixon | Dec 2003 | B2 |
6726720 | Ross et al. | Apr 2004 | B2 |
6733535 | Michelson | May 2004 | B2 |
6755829 | Bono | Jun 2004 | B1 |
6767367 | Michelson | Jul 2004 | B1 |
6770096 | Bolger et al. | Aug 2004 | B2 |
6786903 | Lin | Sep 2004 | B2 |
6800092 | Williams | Oct 2004 | B1 |
6896677 | Lin | May 2005 | B1 |
6923830 | Michelson | Aug 2005 | B2 |
6926737 | Jackson | Aug 2005 | B2 |
6981975 | Michelson | Jan 2006 | B2 |
6986771 | Paul | Jan 2006 | B2 |
6989011 | Paul | Jan 2006 | B2 |
7066961 | Michelson | Jun 2006 | B2 |
7081117 | Bono | Jul 2006 | B2 |
7112206 | Michelson | Sep 2006 | B2 |
7125426 | Moumene | Oct 2006 | B2 |
7141051 | Janowski | Nov 2006 | B2 |
7214243 | Taylor | May 2007 | B2 |
7217293 | Branch, Jr. | May 2007 | B2 |
7223289 | Trieu | May 2007 | B2 |
7264621 | Coates | Sep 2007 | B2 |
7318839 | Malberg et al. | Jan 2008 | B2 |
7338491 | Baker | Mar 2008 | B2 |
7361195 | Schwartz et al. | Apr 2008 | B2 |
7465317 | Malberg et al. | Dec 2008 | B2 |
7503924 | Lee | Mar 2009 | B2 |
7503933 | Michelson | Mar 2009 | B2 |
7559942 | Paul | Jul 2009 | B2 |
7569074 | Eisermann | Aug 2009 | B2 |
7594931 | Louis | Sep 2009 | B2 |
7594932 | Aferzon | Sep 2009 | B2 |
7604656 | Shluzas | Oct 2009 | B2 |
7608095 | Yuan | Oct 2009 | B2 |
7655046 | Dryer | Feb 2010 | B2 |
7678137 | Butler | Mar 2010 | B2 |
7704279 | Moskowitz et al. | Apr 2010 | B2 |
7727279 | Zipnick et al. | Jun 2010 | B2 |
7727280 | McLuen | Jun 2010 | B2 |
7731749 | Biedermann | Jun 2010 | B2 |
7731751 | Butler et al. | Jun 2010 | B2 |
7731753 | Reo et al. | Jun 2010 | B2 |
7744649 | Moore | Jun 2010 | B2 |
7749274 | Razian | Jul 2010 | B2 |
7758644 | Trieu | Jul 2010 | B2 |
7766946 | Bailly | Aug 2010 | B2 |
7766967 | Francis | Aug 2010 | B2 |
7771475 | Michelson | Aug 2010 | B2 |
7776067 | Jackson | Aug 2010 | B2 |
7780703 | Yuan | Aug 2010 | B2 |
7789914 | Michelson | Sep 2010 | B2 |
7811310 | Baker | Oct 2010 | B2 |
7819901 | Yuan | Oct 2010 | B2 |
7833252 | Justis | Nov 2010 | B2 |
7842073 | Richelsoph | Nov 2010 | B2 |
7846188 | Moskowitz et al. | Dec 2010 | B2 |
7857857 | Kim | Dec 2010 | B2 |
7867257 | Na | Jan 2011 | B2 |
7879099 | Zipnick | Feb 2011 | B2 |
7883542 | Zipnick et al. | Feb 2011 | B2 |
7909856 | Yuan | Mar 2011 | B2 |
7909872 | Zipnick et al. | Mar 2011 | B2 |
7942903 | Moskowitz et al. | May 2011 | B2 |
7942910 | Doubler | May 2011 | B2 |
7942911 | Doubler | May 2011 | B2 |
7951173 | Hammill, Sr. | May 2011 | B2 |
7951174 | Kwak | May 2011 | B2 |
7951180 | Moskowitz et al. | May 2011 | B2 |
7955359 | Matthis | Jun 2011 | B2 |
7955363 | Richelsoph | Jun 2011 | B2 |
7967850 | Jackson | Jun 2011 | B2 |
7972363 | Moskowitz et al. | Jul 2011 | B2 |
7972365 | Michelson | Jul 2011 | B2 |
7981157 | Castleman et al. | Jul 2011 | B2 |
7998211 | Baccelli et al. | Aug 2011 | B2 |
8012186 | Pham | Sep 2011 | B2 |
8021430 | Michelson | Sep 2011 | B2 |
8034086 | Iott | Oct 2011 | B2 |
8038702 | Yuan | Oct 2011 | B2 |
8048124 | Chin | Nov 2011 | B2 |
8057519 | Justis | Nov 2011 | B2 |
8062340 | Berrevoets | Nov 2011 | B2 |
8062374 | Markworth et al. | Nov 2011 | B2 |
8062375 | Glerum | Nov 2011 | B2 |
8070812 | Keller | Dec 2011 | B2 |
8070819 | Aferzon | Dec 2011 | B2 |
8075590 | Janowski | Dec 2011 | B2 |
8075599 | Johnson | Dec 2011 | B2 |
8075603 | Hammill, Sr. | Dec 2011 | B2 |
8075618 | Trieu | Dec 2011 | B2 |
8080062 | Armstrong et al. | Dec 2011 | B2 |
8083796 | Raiszadeh et al. | Dec 2011 | B1 |
8100972 | Bruffey | Jan 2012 | B1 |
8105358 | Phan | Jan 2012 | B2 |
8142479 | Hess | Mar 2012 | B2 |
8142508 | Bruffey | Mar 2012 | B1 |
8147556 | Louis | Apr 2012 | B2 |
8162989 | Khalili | Apr 2012 | B2 |
8167793 | Scott | May 2012 | B2 |
8167950 | Aferzon et al. | May 2012 | B2 |
8182539 | Tyber et al. | May 2012 | B2 |
8187332 | McLuen | May 2012 | B2 |
8192495 | Simpson et al. | Jun 2012 | B2 |
8216313 | Moore | Jul 2012 | B2 |
8221502 | Branch, Jr. | Jul 2012 | B2 |
8231676 | Trudeau et al. | Jul 2012 | B2 |
8241294 | Sommerich et al. | Aug 2012 | B2 |
8241341 | Walker | Aug 2012 | B2 |
8241363 | Sommerich et al. | Aug 2012 | B2 |
8257370 | Moskowitz et al. | Sep 2012 | B2 |
8257439 | Zeegers | Sep 2012 | B2 |
8257443 | Kamran et al. | Sep 2012 | B2 |
8267997 | Colleran | Sep 2012 | B2 |
8273125 | Baccelli et al. | Sep 2012 | B2 |
8292958 | Bruffey | Oct 2012 | B1 |
8328870 | Patel | Dec 2012 | B2 |
8343219 | Allain | Jan 2013 | B2 |
8353913 | Moskowitz et al. | Jan 2013 | B2 |
8361148 | Malberg et al. | Jan 2013 | B2 |
8366774 | Bruffey | Feb 2013 | B1 |
8377133 | Yuan et al. | Feb 2013 | B2 |
8377138 | Reo et al. | Feb 2013 | B2 |
8388688 | Moore | Mar 2013 | B2 |
8394145 | Weiman | Mar 2013 | B2 |
8409285 | Keller | Apr 2013 | B2 |
8425528 | Berry et al. | Apr 2013 | B2 |
8435296 | Kadaba et al. | May 2013 | B2 |
8435301 | Gerber et al. | May 2013 | B2 |
8444696 | Michelson | May 2013 | B2 |
8454623 | Patel et al. | Jun 2013 | B2 |
8460388 | Kirwan | Jun 2013 | B2 |
8491658 | Etminan | Jul 2013 | B1 |
8512407 | Butler et al. | Aug 2013 | B2 |
8512409 | Mertens et al. | Aug 2013 | B1 |
8518120 | Glerum | Aug 2013 | B2 |
8523909 | Hess | Sep 2013 | B2 |
8523946 | Swann | Sep 2013 | B1 |
8540769 | Janowski et al. | Sep 2013 | B2 |
8545562 | Materna et al. | Oct 2013 | B1 |
8545563 | Brun et al. | Oct 2013 | B2 |
8556979 | Glerum | Oct 2013 | B2 |
8579982 | Michelson | Nov 2013 | B2 |
8597353 | Kana et al. | Dec 2013 | B2 |
8597357 | Trudeau et al. | Dec 2013 | B2 |
8597360 | McLuen et al. | Dec 2013 | B2 |
8617245 | Brett | Dec 2013 | B2 |
8679183 | Glerum | Mar 2014 | B2 |
8685098 | Glerum | Apr 2014 | B2 |
8685104 | Lee et al. | Apr 2014 | B2 |
8696751 | Ashley et al. | Apr 2014 | B2 |
8698405 | Kirwan | Apr 2014 | B2 |
8709086 | Glerum | Apr 2014 | B2 |
8715350 | Janowski et al. | May 2014 | B2 |
8734516 | Moskowitz et al. | May 2014 | B2 |
8747444 | Moskowitz et al. | Jun 2014 | B2 |
8753394 | Zipnick et al. | Jun 2014 | B2 |
8795335 | Abdou et al. | Aug 2014 | B1 |
8795367 | Zipnick | Aug 2014 | B2 |
8795368 | Trieu et al. | Aug 2014 | B2 |
8814879 | Trieu et al. | Aug 2014 | B2 |
8828018 | Ragab et al. | Sep 2014 | B2 |
8845738 | Michelson | Sep 2014 | B2 |
8858638 | Michelson | Oct 2014 | B2 |
8864829 | Bruffey et al. | Oct 2014 | B1 |
8864833 | Glerum | Oct 2014 | B2 |
8888853 | Glerum | Nov 2014 | B2 |
8888854 | Glerum | Nov 2014 | B2 |
8894710 | Simpson et al. | Nov 2014 | B2 |
8900310 | Carlson et al. | Dec 2014 | B2 |
8906101 | Lee et al. | Dec 2014 | B2 |
8920505 | Aferzon et al. | Dec 2014 | B2 |
8932355 | Grotz et al. | Jan 2015 | B2 |
8932359 | Brett | Jan 2015 | B2 |
8940048 | Butler et al. | Jan 2015 | B2 |
8956413 | Ashley et al. | Feb 2015 | B2 |
8961605 | Zipnick | Feb 2015 | B2 |
8968405 | Kirwan | Mar 2015 | B2 |
8979933 | Mshnubholta et al. | Mar 2015 | B2 |
8986384 | Malberg et al. | Mar 2015 | B2 |
8992620 | Ashley et al. | Mar 2015 | B2 |
8998920 | Berry et al. | Apr 2015 | B2 |
9005293 | Moskowitz et al. | Apr 2015 | B2 |
9034041 | Wolters et al. | May 2015 | B2 |
9039770 | Aferzon et al. | May 2015 | B2 |
9039771 | Glerum | May 2015 | B2 |
9107760 | Walters | Aug 2015 | B2 |
9107761 | Lee et al. | Aug 2015 | B2 |
9114020 | Arginteanu | Aug 2015 | B2 |
9119732 | Schifano et al. | Sep 2015 | B2 |
9155553 | Zipnick | Oct 2015 | B2 |
9168033 | Hess | Oct 2015 | B2 |
9168152 | Raiszadeh et al. | Oct 2015 | B2 |
9186262 | McLuen et al. | Nov 2015 | B2 |
9198764 | Greenberg et al. | Dec 2015 | B2 |
9198771 | Ciupik | Dec 2015 | B2 |
9198774 | Pisharodi | Dec 2015 | B2 |
9211196 | Glerum | Dec 2015 | B2 |
9220606 | Janowski et al. | Dec 2015 | B2 |
9226836 | Glerum | Jan 2016 | B2 |
9233011 | Trudeau et al. | Jan 2016 | B2 |
9248028 | Gamache | Feb 2016 | B2 |
9283085 | Greenberg et al. | Mar 2016 | B2 |
9283087 | Lee et al. | Mar 2016 | B2 |
9289308 | Marino et al. | Mar 2016 | B2 |
9301854 | Moskowitz et al. | Apr 2016 | B2 |
9351847 | Reed et al. | May 2016 | B2 |
9364342 | Walkenhorst et al. | Jun 2016 | B2 |
9370435 | Walkenhorst et al. | Jun 2016 | B2 |
9375239 | Abdou | Jun 2016 | B2 |
9463091 | Brett | Oct 2016 | B2 |
9566163 | Suddaby et al. | Feb 2017 | B2 |
9675470 | Packer et al. | Jun 2017 | B2 |
9707100 | Duffield et al. | Jul 2017 | B2 |
9730802 | Harvey | Aug 2017 | B1 |
9757164 | Hess | Sep 2017 | B2 |
20020120272 | Yuan | Aug 2002 | A1 |
20030004511 | Ferree | Jan 2003 | A1 |
20030109928 | Pasquet | Jun 2003 | A1 |
20030125742 | Yuan | Jul 2003 | A1 |
20030135279 | Michelson | Jul 2003 | A1 |
20030149484 | Michelson | Aug 2003 | A1 |
20030187433 | Lin | Oct 2003 | A1 |
20030187434 | Lin | Oct 2003 | A1 |
20030187436 | Bolger et al. | Oct 2003 | A1 |
20040010312 | Enayati | Jan 2004 | A1 |
20040133280 | Trieu | Jul 2004 | A1 |
20040153068 | Janowski | Aug 2004 | A1 |
20040236330 | Purcell | Nov 2004 | A1 |
20040254644 | Taylor | Dec 2004 | A1 |
20050027362 | Williams et al. | Feb 2005 | A1 |
20050033296 | Bono | Feb 2005 | A1 |
20050033429 | Kuo | Feb 2005 | A1 |
20050049590 | Alleyne | Mar 2005 | A1 |
20050060036 | Schultz et al. | Mar 2005 | A1 |
20050107788 | Beaurain | May 2005 | A1 |
20050125062 | Biedermann et al. | Jun 2005 | A1 |
20050131410 | Lin | Jun 2005 | A1 |
20050143825 | Enayati | Jun 2005 | A1 |
20050177154 | Moumene | Aug 2005 | A1 |
20050187548 | Butler | Aug 2005 | A1 |
20050197760 | Kaga | Sep 2005 | A1 |
20050228385 | Iott | Oct 2005 | A1 |
20050283157 | Coates | Dec 2005 | A1 |
20050288671 | Yuan | Dec 2005 | A1 |
20060004357 | Lee | Jan 2006 | A1 |
20060025767 | Khalili | Feb 2006 | A1 |
20060069436 | Sutton et al. | Mar 2006 | A1 |
20060095136 | McLuen | May 2006 | A1 |
20060129149 | Iott | Jun 2006 | A1 |
20060149241 | Richelsoph | Jul 2006 | A1 |
20060161152 | Ensign | Jul 2006 | A1 |
20060217716 | Baker | Sep 2006 | A1 |
20060241764 | Michelson | Oct 2006 | A1 |
20060247636 | Yuan | Nov 2006 | A1 |
20060247776 | Kim | Nov 2006 | A1 |
20060264933 | Baker | Nov 2006 | A1 |
20060276789 | Jackson | Dec 2006 | A1 |
20060276899 | Zipnick et al. | Dec 2006 | A1 |
20060276901 | Zipnick et al. | Dec 2006 | A1 |
20060276902 | Zipnick et al. | Dec 2006 | A1 |
20060282074 | Renaud | Dec 2006 | A1 |
20060293665 | Shluzas | Dec 2006 | A1 |
20070050032 | Gittings et al. | Mar 2007 | A1 |
20070055235 | Janowski | Mar 2007 | A1 |
20070055241 | Matthis | Mar 2007 | A1 |
20070088357 | Johnson | Apr 2007 | A1 |
20070161999 | Biedermann | Jul 2007 | A1 |
20070162130 | Rashbaum | Jul 2007 | A1 |
20070213731 | Prusmack | Sep 2007 | A1 |
20070233078 | Justis | Oct 2007 | A1 |
20070233080 | Na | Oct 2007 | A1 |
20070270813 | Garamszegi | Nov 2007 | A1 |
20070270960 | Bonin et al. | Nov 2007 | A1 |
20070270961 | Ferguson | Nov 2007 | A1 |
20070282341 | Hes | Dec 2007 | A1 |
20080015580 | Chao | Jan 2008 | A1 |
20080015584 | Richelsoph | Jan 2008 | A1 |
20080015597 | Whipple | Jan 2008 | A1 |
20080021562 | Huppert | Jan 2008 | A1 |
20080027550 | Link et al. | Jan 2008 | A1 |
20080045953 | Garamszegi | Feb 2008 | A1 |
20080045955 | Berrevoets | Feb 2008 | A1 |
20080051901 | deVilliers | Feb 2008 | A1 |
20080051902 | Dwyer | Feb 2008 | A1 |
20080133017 | Beyar et al. | Jun 2008 | A1 |
20080147121 | Justis | Jun 2008 | A1 |
20080167716 | Schwartz et al. | Jul 2008 | A1 |
20080177322 | Davis | Jul 2008 | A1 |
20080177332 | Reiley | Jul 2008 | A1 |
20080183215 | Altarac | Jul 2008 | A1 |
20080195159 | Kloss | Aug 2008 | A1 |
20080200956 | Beckwith | Aug 2008 | A1 |
20080234686 | Beaurain | Sep 2008 | A1 |
20080287998 | Doubler | Nov 2008 | A1 |
20080294203 | Kovach | Nov 2008 | A1 |
20080312743 | Vila | Dec 2008 | A1 |
20090030457 | Janowski | Jan 2009 | A1 |
20090036929 | Reglos | Feb 2009 | A1 |
20090062866 | Jackson | Mar 2009 | A1 |
20090082819 | Blain | Mar 2009 | A1 |
20090164020 | Janowski | Jun 2009 | A1 |
20090182430 | Tyber | Jul 2009 | A1 |
20090198241 | Phan | Aug 2009 | A1 |
20090198245 | Phan | Aug 2009 | A1 |
20090198338 | Phan | Aug 2009 | A1 |
20090265007 | Colleran | Oct 2009 | A1 |
20090270992 | Gerber et al. | Oct 2009 | A1 |
20090292316 | Hess | Nov 2009 | A1 |
20090306720 | Doubler | Dec 2009 | A1 |
20090318974 | Yuan | Dec 2009 | A1 |
20100004694 | Little | Jan 2010 | A1 |
20100010547 | Beaurain | Jan 2010 | A1 |
20100016974 | Janowski | Jan 2010 | A1 |
20100063552 | Chin | Mar 2010 | A1 |
20100094352 | Iott | Apr 2010 | A1 |
20100114318 | Gittings et al. | May 2010 | A1 |
20100137920 | Hammill | Jun 2010 | A1 |
20100145455 | Simpson et al. | Jun 2010 | A1 |
20100145459 | McDonough et al. | Jun 2010 | A1 |
20100161057 | Berry et al. | Jun 2010 | A1 |
20100185289 | Kirwan | Jul 2010 | A1 |
20100185292 | Hochschuler et al. | Jul 2010 | A1 |
20100191246 | Howald et al. | Jul 2010 | A1 |
20100198273 | Kwak | Aug 2010 | A1 |
20100204737 | Bae | Aug 2010 | A1 |
20100249933 | Trieu | Sep 2010 | A1 |
20100249935 | Slivka et al. | Sep 2010 | A1 |
20100268280 | Yuan | Oct 2010 | A1 |
20100280618 | Jodaitis | Nov 2010 | A1 |
20100305704 | Messerli | Dec 2010 | A1 |
20100312279 | Gephart | Dec 2010 | A1 |
20110009911 | Hammill | Jan 2011 | A1 |
20110015742 | Hong | Jan 2011 | A1 |
20110015745 | Bucci | Jan 2011 | A1 |
20110035007 | Patel | Feb 2011 | A1 |
20110077739 | Rashbaum | Mar 2011 | A1 |
20110093074 | Glerum et al. | Apr 2011 | A1 |
20110098747 | Donner | Apr 2011 | A1 |
20110106166 | Keyer | May 2011 | A1 |
20110118840 | Huntsman | May 2011 | A1 |
20110125196 | Quevedo | May 2011 | A1 |
20110137349 | Moskowitz et al. | Jun 2011 | A1 |
20110144701 | Altarac | Jun 2011 | A1 |
20110160779 | Schlaepfer | Jun 2011 | A1 |
20110160866 | Laurence | Jun 2011 | A1 |
20110166655 | Michelson | Jul 2011 | A1 |
20110196431 | Chao | Aug 2011 | A1 |
20110196494 | Yedlicka et al. | Aug 2011 | A1 |
20110202135 | Baek et al. | Aug 2011 | A1 |
20110208250 | Kwak | Aug 2011 | A1 |
20110208311 | Janowski | Aug 2011 | A1 |
20110208312 | Moskowitz et al. | Aug 2011 | A1 |
20110218579 | Jackson | Sep 2011 | A1 |
20110230970 | Lynn et al. | Sep 2011 | A1 |
20110230971 | Donner | Sep 2011 | A1 |
20110270325 | Keyer | Nov 2011 | A1 |
20110307016 | Reglos | Dec 2011 | A1 |
20110313528 | Laubert | Dec 2011 | A1 |
20120010714 | Moskowitz et al. | Jan 2012 | A1 |
20120016477 | Metcalf et al. | Jan 2012 | A1 |
20120029569 | Iott | Feb 2012 | A1 |
20120029578 | Suh | Feb 2012 | A1 |
20120029644 | Markworth et al. | Feb 2012 | A1 |
20120035729 | Glerum | Feb 2012 | A1 |
20120053693 | Zeegers | Mar 2012 | A1 |
20120078371 | Gamache | Mar 2012 | A1 |
20120078373 | Gamache et al. | Mar 2012 | A1 |
20120095559 | Woods et al. | Apr 2012 | A1 |
20120109318 | Gittings et al. | May 2012 | A1 |
20120116466 | Dinville | May 2012 | A1 |
20120143341 | Zipnick | Jun 2012 | A1 |
20120150300 | Nihalani | Jun 2012 | A1 |
20120150304 | Glerum | Jun 2012 | A1 |
20120150305 | Glerum | Jun 2012 | A1 |
20120158146 | Glerum | Jun 2012 | A1 |
20120158148 | Glerum | Jun 2012 | A1 |
20120185049 | Varela | Jul 2012 | A1 |
20120191196 | Louis | Jul 2012 | A1 |
20120215315 | Hochschuler et al. | Aug 2012 | A1 |
20120265248 | Delecrin | Oct 2012 | A1 |
20120265258 | Garvey | Oct 2012 | A1 |
20120277867 | Kana et al. | Nov 2012 | A1 |
20120277878 | Sommerich et al. | Nov 2012 | A1 |
20120296428 | Donner | Nov 2012 | A1 |
20120303064 | Walker | Nov 2012 | A1 |
20120330417 | Zipnick | Dec 2012 | A1 |
20120330419 | Moskowitz et al. | Dec 2012 | A1 |
20120330424 | Zeegers | Dec 2012 | A1 |
20120330425 | Zipnick | Dec 2012 | A1 |
20130013006 | Rashbaum | Jan 2013 | A1 |
20130018468 | Moskowitz et al. | Jan 2013 | A1 |
20130018469 | Moskowitz et al. | Jan 2013 | A1 |
20130023991 | Moskowitz et al. | Jan 2013 | A1 |
20130041408 | Dinville | Feb 2013 | A1 |
20130053891 | Hawkins | Feb 2013 | A1 |
20130053962 | Moskowitz et al. | Feb 2013 | A1 |
20130110242 | Kirwan | May 2013 | A1 |
20130150968 | Dinville | Jun 2013 | A1 |
20130150969 | Zipnick | Jun 2013 | A1 |
20130166029 | Dinville | Jun 2013 | A1 |
20130268076 | Carlson et al. | Oct 2013 | A1 |
20130274883 | McLuen et al. | Oct 2013 | A1 |
20130310935 | Swann | Nov 2013 | A1 |
20130338776 | Jones | Dec 2013 | A1 |
20140074214 | Raje et al. | Mar 2014 | A1 |
20140074241 | McConnell | Mar 2014 | A1 |
20140088711 | Chin et al. | Mar 2014 | A1 |
20140100663 | Messerli et al. | Apr 2014 | A1 |
20140114420 | Robinson | Apr 2014 | A1 |
20140121773 | Patel et al. | May 2014 | A1 |
20140148904 | Robinson | May 2014 | A1 |
20140148905 | Messerli et al. | May 2014 | A1 |
20140163682 | Lott et al. | Jun 2014 | A1 |
20140163683 | Seifert et al. | Jun 2014 | A1 |
20140172104 | Dugal et al. | Jun 2014 | A1 |
20140180417 | Bergey | Jun 2014 | A1 |
20140236297 | Iott | Aug 2014 | A1 |
20140249629 | Moskowitz et al. | Sep 2014 | A1 |
20140277509 | Robinson et al. | Sep 2014 | A1 |
20140277510 | Robinson et al. | Sep 2014 | A1 |
20140303731 | Glerum | Oct 2014 | A1 |
20140324171 | Glerum | Oct 2014 | A1 |
20140371795 | Hess et al. | Dec 2014 | A1 |
20140379085 | Duffield | Dec 2014 | A1 |
20150012097 | Ibarra | Jan 2015 | A1 |
20150018952 | Ali | Jan 2015 | A1 |
20150025637 | Moskowitz et al. | Jan 2015 | A1 |
20150045893 | Dinville et al. | Feb 2015 | A1 |
20150100127 | Bal et al. | Apr 2015 | A1 |
20150105824 | Moskowitz et al. | Apr 2015 | A1 |
20150127107 | Kim | May 2015 | A1 |
20150127109 | Brett et al. | May 2015 | A1 |
20150134064 | Grotz et al. | May 2015 | A1 |
20150142116 | Aferzon et al. | May 2015 | A1 |
20150202051 | Tanaka | Jul 2015 | A1 |
20150209089 | Chataigner et al. | Jul 2015 | A1 |
20150250603 | Glerum | Sep 2015 | A9 |
20150250611 | Schifano et al. | Sep 2015 | A1 |
20150250612 | Schifano et al. | Sep 2015 | A1 |
20150265415 | Gittings et al. | Sep 2015 | A1 |
20150265416 | Aferzon et al. | Sep 2015 | A1 |
20150272743 | Jimenez et al. | Oct 2015 | A1 |
20150289988 | Ashley et al. | Oct 2015 | A1 |
20150305880 | Kim | Oct 2015 | A1 |
20150305887 | McAtamney et al. | Oct 2015 | A1 |
20150320568 | Ameil et al. | Nov 2015 | A1 |
20150335372 | Schifano et al. | Nov 2015 | A1 |
20150342754 | Geebelen et al. | Dec 2015 | A1 |
20150374507 | Wolters et al. | Dec 2015 | A1 |
20160015526 | Ali | Jan 2016 | A1 |
20160030191 | McLuen et al. | Feb 2016 | A1 |
20160038299 | Chen | Feb 2016 | A1 |
20160038845 | Mizunaga et al. | Feb 2016 | A1 |
20160045326 | Hansen et al. | Feb 2016 | A1 |
20160045327 | Robinson et al. | Feb 2016 | A1 |
20160058565 | Zappacosta et al. | Mar 2016 | A1 |
20160074172 | Lee et al. | Mar 2016 | A1 |
20160081813 | Greenberg et al. | Mar 2016 | A1 |
20160100953 | Dinville et al. | Apr 2016 | A1 |
20160106550 | Slivka et al. | Apr 2016 | A1 |
20160113777 | Gamache | Apr 2016 | A1 |
20160120657 | Trudeau et al. | May 2016 | A1 |
20160151171 | Mozeleski et al. | Jun 2016 | A1 |
20160166395 | Weiman | Jun 2016 | A9 |
20160175107 | Janowski et al. | Jun 2016 | A1 |
20160338845 | Ashleigh | Nov 2016 | A1 |
20160374831 | Duffield | Dec 2016 | A1 |
20170056192 | Buss | Mar 2017 | A1 |
20170100260 | Duffield et al. | Apr 2017 | A1 |
20170165082 | Faulhaber | Jun 2017 | A1 |
20170165083 | Greenhalgh | Jun 2017 | A1 |
20170266016 | Faulhaber | Sep 2017 | A1 |
20170281358 | Wagner et al. | Oct 2017 | A1 |
20170296238 | Snell et al. | Oct 2017 | A1 |
20170303975 | Koch et al. | Oct 2017 | A1 |
20180104068 | Sack | Apr 2018 | A1 |
20180110627 | Sack | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
2013267749 | Dec 2013 | AU |
2730337 | Oct 2005 | CN |
101854887 | Oct 2010 | CN |
102596109 | Jul 2012 | CN |
104822332 | Aug 2015 | CN |
105188580 | Dec 2015 | CN |
105250056 | Jan 2016 | CN |
2389902 | Nov 2011 | EP |
2015077467 | Jul 2014 | JP |
2015501189 | Jan 2015 | JP |
2016524988 | Aug 2016 | JP |
2010092893 | Aug 2010 | WO |
2010092893 | Aug 2010 | WO |
2011035126 | Mar 2011 | WO |
2012047289 | Apr 2012 | WO |
2012117312 | Sep 2012 | WO |
2013062716 | May 2013 | WO |
2016010499 | Jan 2016 | WO |
2016210434 | Dec 2016 | WO |
Entry |
---|
Office Action dated Apr. 9, 2020 in U.S. Appl. No. 16/109,326. |
International Search Report and Written Opinion dated Jan. 12, 2018 for International Patent Application No. PCT/US2017/56973. |
International Search Report and Written Opinion dated Jan. 23, 2018 for International Patent Application No. PCT/US2017/058109. |
International Search Report and Written Opinion dated Dec. 18, 2019 for International Patent Application No. PCT/US2019/47714. |
Office Action dated Sep. 3, 2020 in JP Application No. 2019-520880. |
Office Action dated Jun. 9, 2020 in U.S. Appl. No. 15/996,189. |
Supplementary Partial European Search Report for EP 17 86 5409, dated Jun. 19, 2020 (17 pp). |
Supplementary Partial European Search Report for EP 17 86 3072, dated Jun. 25, 2020 (17 pp). |
Office Action dated Dec. 30, 2020 in CN Application No. 2017800781366. |
Supplementary European Search Report dated Oct. 30, 2020 in EP Application No. EP 17865409. |
Office Action dated Nov. 30, 2020 in CN Application No. 2017800805892. |
Office Action dated Jun. 17, 2021 in CN Application No. 2017800805892. |
Office Action dated Jan. 5, 2021 in JP Application No. 2019543189. |
Office Action dated Jun. 24, 2021 in U.S. Appl. No. 16/429,278. |
Office Action dated Oct. 21, 2021 in U.S. Appl. No. 16/659,031. |
International Search Report and Written Opinion dated Aug. 25, 2016 for International Application No. PCT/US2016/039642. |
Number | Date | Country | |
---|---|---|---|
20200015986 A1 | Jan 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15333892 | Oct 2016 | US |
Child | 16565003 | US |